Massachusetts Biomedical Initiatives

TransCode Therapeutics, Inc., an RNA oncology company, announced on July 13 it would close its initial public offering of nearly 7.2 million shares at $4 per share. 

In Worcester Business Journal's annual list of the most influential people in the Central Massachusetts economy, the Power 50, one-third of those listed have ties to the manufacturing industry.

The Worcester life sciences incubator Massachusetts Biomedical Initiatives has won a $252,000 federal grant to help spur regional economic development and biomedical entrepreneurship.

This year’s 40 Under Forty class is certainly like no other. Although full of the archetypal up-and-coming leaders of Central Massachusetts business organizations, each member of the Class of 2020 has found a way to thrive in the midst of an international crisis.

Inside dozens of closet-sized laboratories in three different Worcester buildings is a goldmine of biotechnology brainpower and...

Thanks to several decades of hard work and planning and the growth of life science business parks in Worcester, the biotech cluster in Central Massachusetts is becoming known on the world stage.

Jon Weaver took over as president and CEO of Worcester biotech incubator Massachusetts Biomedical Initiatives after Kevin O’Sullivan retired at the end of 2018 after two decades leading the agency.

HDL Therapeutics, a Worcester startup working on a treatment for arterial diseases related to build up of fatty material, had positive results in its first clinical trial.

A new West Boylston facility will enable the company to continue growing at its current pace, including for up to 20 more employees in the near term, Cogmedix President and CEO Chris Coghlin recently told WBJ.

Worcester medical device contract manufacturer Cogmedix is expanding its facilities and moving into a new headquarters at an 80,000-square-foot building in West Boylston.